Drug Profile
Research programme: eye disorders therapeutics - Pfizer
Latest Information Update: 03 Aug 2009
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 03 Aug 2009 Discontinued - Preclinical for Eye disorders in USA (unspecified route)
- 20 Jan 2006 Angiosyn has been acquired by Pfizer
- 16 Feb 2005 Preclinical trials in Eye disorders in USA (unspecified route)